Mr Patrick Ajah, the Managing Director of May & Baker Nigeria Plc has stated that the company is commited to enhancing healthy living for Nigerians through the production of quality and international standard medical products.
made this known at the company’s 2024 Customer Forum on Tuesday night in Lagos.
The company at the event also unveiled a new cough syrup.

The News Agency of Nigeria (NAN) reports that the theme of the programme was: “Boundless Possibilities.”
While delivering his speech of welcome, Ajah said the newly introduced MAYSEDYL Expectorant (cough syrup) was carefully prepared to meet the international standard and recommendations of the World Health Organisation.
According to him, May & Baker plans to launch at least seven new brands of products before the end of June 2024.

Ajah, who appreciated the company’s distributors and customers for their steadfast patronage and support, noted that the 2023 business year was quite challenging.
He explained that the fluctuating nature of the foreign exchange market, inflation, fuel subsidy removal and unsteady power supply, among other challenges, contributed to the high cost of production materials.

“The year 2023 was quite challenging. A lot of pharmaceutical manufacturing companies left, but by the Grace of God, we remained in business.
“So, I appreciate all our distributors and customers for their steadfast support and we are committed to serving you better going forward.

“In this year 2024, at least, seven new brands of production will be launched. And this occasion of 2024 Customer Forum is very significant because this year, May & Baker will be marking its 80 years anniversary,” Ajah said.
The Head, Marketing and Sales, May & Baker, Mr Obinna Emeribe, said that distributors and customers were an integral part of the company.
Reviewing 2023 business operations, Emeribe said the distributors contributed N15.7 billion of the total revenue generated by the company.